Press release
United States Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market 2025 Report | Dr. Reddy's Laboratories Ltd., Thermo Fisher Scientific Inc., Biosynth, Affgility Solutions, Conscientia Industrial Co. Ltd
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment
DataM Intelligence has released its latest report on the "Metabolic Dysfinction Associates Steatohepatitis Mash Treatment Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.
The drug segment held about 54.3% of the global metabolic dysfunction-associated steatohepatitis treatment market, while North America contributed approximately 43.2% of the global market share.
Eli Lilly's Phase II SYNERGY-NASH study showed that at 52 weeks, 51.8% of patients on 5 mg tirzepatide, 62.8% on 10 mg, and 73.3% on 15 mg achieved absence of metabolic dysfunction-associated steatohepatitis (MASH) without fibrosis worsening, compared to 13.2% with placebo.
US biopharmaceutical company 89bio has initiated the Phase III ENLIGHTEN-Cirrhosis trial of pegozafermin to treat metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/metabolic-dysfunction-associated-steatohepatitis-treatment-market?kb
Key Player:
Madrigal Pharmaceuticals, Simson Pharma Limited, Dr. Reddy's Laboratories Ltd., Thermo Fisher Scientific Inc., Biosynth, Affgility Solutions, Conscientia Industrial Co. Ltd., Smolecule Inc., 89 Bio Inc., and Sandoo Pharmaceuticals and Chemicals Co. Ltd.
Latest M&A
Novo Nordisk announced a $5.2 billion acquisition of Akero Therapeutics in 2025, strengthening its metabolic disease franchise with Akero's late-stage FGF21 analog efruxifermin targeting moderate to severe MASH. The deal is expected to close by end-2025 and expands Novo Nordisk's portfolio beyond diabetes and obesity.
Roche entered a definitive agreement to acquire 89bio, a developer of FGF21 analog BKMF-3 for MASH treatment, enhancing its presence in liver diseases.
Other mid-sized deals involve biotech firms working on thyroid hormone receptor beta agonists or combination therapies for MASH.
Forecast Projection:
The global Metabolic Dysfinction Associates Steatohepatitis Mash Treatment market is set to witness strong growth from 2025 to 2032. After maintaining steady momentum in 2024, the market is expected to accelerate as key industry players implement strategic initiatives to boost adoption. Companies that adapt to these emerging trends will be well-positioned to capture new opportunities and enhance their revenue potential throughout the forecast period.
Market Intelligence Research Process:
The Metabolic Dysfinction Associates Steatohepatitis Mash Treatment Market Report by DataM Intelligence offers a comprehensive analysis built on a mix of primary and secondary research. It explores key factors driving the industry, including government policies, market trends, competitive landscape, technological advancements, and upcoming innovations. This in-depth study uncovers both growth opportunities and potential challenges, helping businesses navigate market fluctuations and make data-driven decisions for sustainable success.
Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=metabolic-dysfunction-associated-steatohepatitis-treatment-market?kb
Key Segmentations:
By Treatment: Drug , Rezdiffra
By Therapy; Phytic Acid Based Nano-Medicine Therapy, Weight Management, Diabetes Control, Regular Exercise, Others
By End-User: Hospitals, Specialty Clinics, Homecare, Others
Latest News & Developments
The FDA approved semaglutide (Wegovy) for treatment of adults with non-cirrhotic MASH and stage 2 or 3 liver fibrosis in August 2025 based on the ESSENCE trial data demonstrating significant liver fat reduction and fibrosis improvement.
Resmetirom (Rezdiffra; Madrigal Pharmaceuticals), a thyroid hormone receptor beta agonist, gained approval in 2024 and offers a targeted approach to reduce liver fat, inflammation, and fibrosis, potentially reducing liver transplants.
Multiple promising candidates, including VK2809, VK2735, and efruxifermin, are advancing through clinical trials aiming to address different MASH disease stages and co-morbidities.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/metabolic-dysfunction-associated-steatohepatitis-treatment-market?kb
FAQ's
Q1: How large is the Metabolic Dysfinction Associates Steatohepatitis Mash Treatment Market?
Ans: The Metabolic Dysfinction Associates Steatohepatitis Mash Treatment Market size was valued at US$ 1.67 billion in 2023 and is projected to grow to US$ 7.64 billion by 2031.
Q2: How quickly is the Metabolic Dysfinction Associates Steatohepatitis Mash Treatment Market expanding?
Ans: The Metabolic Dysfinction Associates Steatohepatitis Mash Treatment Market is forecasted to grow at a CAGR of 21.8% between 2025 and 2032, showing Annual growth momentum
Q3: Which regions are dominating the Metabolic Dysfinction Associates Steatohepatitis Mash Treatment Market and which are fastest-growing?
Ans: North America dominating the Metabolic Dysfinction Associates Steatohepatitis Mash Treatment market.
Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/metabolic-dysfunction-associated-steatohepatitis-treatment-market?kb
FDA Approvals and Guidance
The FDA approved semaglutide for MASH treatment in 2025, enabling earlier intervention with an anti-obesity and anti-inflammatory GLP-1 receptor agonist in liver disease.
FDA accepted surrogate endpoints related to liver biomarkers and imaging for accelerated approval pathways in MASH drug development.
Updated clinical guidelines emphasize lifestyle management alongside MASH pharmacotherapy.
Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb
Reimbursement
The reimbursement landscape is evolving with Medicare and private payer coverage expanding for semaglutide and resmetirom for MASH indications, though pricing and patient adherence remain key focus areas.
Europe's EMA has yet to approve any MASH-specific therapies; resmetirom has received conditional authorization in some countries pending real-world outcomes.
China and other emerging markets are increasing reimbursement listings for NASH/MASH drugs as prevalence rises.
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market 2025 Report | Dr. Reddy's Laboratories Ltd., Thermo Fisher Scientific Inc., Biosynth, Affgility Solutions, Conscientia Industrial Co. Ltd here
News-ID: 4261515 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Polymerase Chain Reaction (PCR) Market Rapid Growt 2025-2033: Most Leading Compa …
polymerase chain reaction market size reached US$ 11.58 Billion in 2023 with a rise of US$ 12.33 Billion in 2024 and is expected to reach US$ 22.66 Billion by 2033, growing at a CAGR of 7.0% during the forecast period 2025-2033.
Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/polymerase-chain-reaction-market?kb
United States: Recent Industry Developments
✅ November 2025: Thermo Fisher Scientific launched an ultra-fast PCR system…
Transformer Monitoring Systems Industry Trends Shaping Energy Sector | Most Lead …
DataM Intelligence has published a new research report on "Transformer Monitoring Systems Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Sample PDF Of This Report…
Future of Performance Elastomers Market Through 2032: Most Leading Companies - Z …
DataM Intelligence has published a new research report on "Performance Elastomer Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Sample PDF Of This Report (Get…
Wireless Charging Market to Reach US$ 60.7 Billion by 2031 | Strong 27.3% CAGR | …
The Global Wireless Charging Market was valued at US$ 8.9 billion in 2023 and is projected to reach US$ 60.7 billion by 2031, growing at a CAGR of 27.3% during the forecast period 2024-2031. The market is experiencing strong momentum driven by the rapid adoption of smartphones, wearables, electric vehicles, and smart home devices, all of which increasingly rely on convenient, cable-free power solutions. Expanding consumer preference for seamless charging…
More Releases for MASH
Key Trends Reshaping the Metabolic Dysfunction-Associated Steatohepatitis (MASH) …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size pertaining to treatments for metabolic dysfunction-associated steatohepatitis (MASH) has witnessed substantial expansion lately, projected to surge from its 2024 valuation of $2 billion euros to $2.59 billion euros by 2025, reflecting a…
MASH Market Momentum: Late-Stage Assets Fuel Competitive Therapeutic Landscape
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Nonalcoholic Steatohepatitis (NASH), is becoming an increasingly urgent global public health issue. This progressive liver disease, characterized by fat buildup in the liver unrelated to alcohol consumption, can lead to inflammation (hepatitis), fibrosis, cirrhosis, and eventually liver cancer.
Download Strategic Sample PDF: https://datamintelligence.com/strategic-insights/sample/metabolic-dysfunction-associated-steatohepatitis-mash?ophp
Akero Therapeutics Completes Enrollment for Double-Blind Phase III SYNCHRONY Real-World Study of Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD…
Pepper Mash Market Size Estimated to grow USD 0.517 Billion by 2032
Pepper Mash Market Overview
The pepper mash market is a dynamic segment of the global food industry, characterized by its rich flavor profiles and wide-ranging applications. Pepper mash, a key ingredient in the production of hot sauces, seasonings, and processed foods, has gained significant traction due to its ability to impart heat and complexity to various dishes. This blog delves into the market overview, competitive landscape, key drivers, segmentation, and regional…
Fermented Pepper Mash Market Revenue, Insights, Overview, Outlook, Analysis | Va …
Fermented Pepper Mash Market
Fermented Pepper Mash is one of the most commonly used ingredients in kitchens and hot sauce manufacturers. This product is ideal for making medium-heat hot sauces and marinades. One can add small amounts to stews, soups and pastes to give them a mild flavor. Additionally, people can create their own homemade sauce by adding garlic, onions, vinegar, sugar, lemon juice, and more ingredients.
According to new survey, global…
Pepper Mash Market Production, Consumption, Export-Import Analysis Through 2030
** Market Overview **
Pepper mash refers to a mixture of ground black peppercorns in brine, vinegar or other solutions that is used to impart flavor, spice and heat to various food products. It is used in sauces, marinades, snacks, meat products and other culinary applications across the world.
The growth of the global pepper mash market is being driven by rising demand for convenience foods, growing adoption of international cuisines and…
Mash Tun Media: New UK Marketing Agency working exclusively with breweries
Mash Tun Media, the latest and most focused Digital Marketing Agency for Microbreweries has been developed and launched by the team at Future State Media.
Developing niche-specific skills and understanding of the unique demands of the microbrewing market has been a passion of the team at Future State Media for the past year. Working in the brewing niche has aligned so well with existing successful projects where the team had…
